6.66
price up icon0.41%   0.00
 
loading
Organon Co stock is traded at $6.66, with a volume of 2.65M. It is up +0.41% in the last 24 hours and down -35.39% over the past month. Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$6.66
Open:
$6.67
24h Volume:
2.65M
Relative Volume:
0.56
Market Cap:
$1.73B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
2.4738
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
-25.20%
1M Performance:
-35.39%
6M Performance:
-49.18%
1Y Performance:
-62.54%
1-Day Range:
Value
$6.64
$6.84
1-Week Range:
Value
$6.39
$9.28
52-Week Range:
Value
$6.39
$19.05

Organon Co Stock (OGN) Company Profile

Name
Name
Organon Co
Name
Phone
551-430-6000
Name
Address
30 HUDSON STREET, JERSEY CITY
Name
Employee
10,000
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
OGN's Discussions on Twitter

Compare OGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
OGN
Organon Co
6.665 1.73B 6.28B 700.00M 537.00M 2.6922
Drug Manufacturers - General icon
LLY
Lilly Eli Co
820.96 735.18B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
185.61 450.37B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
226.07 401.96B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
122.41 238.94B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.92 217.38B 63.43B 16.42B 14.72B 6.4861

Organon Co Stock (OGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-27-25 Downgrade Piper Sandler Overweight → Underweight
May-02-25 Downgrade Evercore ISI Outperform → In-line
Sep-06-24 Downgrade JP Morgan Neutral → Underweight
Nov-03-23 Downgrade Goldman Buy → Neutral
Sep-21-23 Initiated Barclays Overweight
Mar-16-23 Initiated Raymond James Outperform
Oct-14-22 Downgrade BofA Securities Neutral → Underperform
Sep-06-22 Upgrade Piper Sandler Neutral → Overweight
Aug-05-22 Downgrade BofA Securities Buy → Neutral
Apr-27-22 Initiated Goldman Buy
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Oct-07-21 Initiated Piper Sandler Neutral
Sep-01-21 Initiated BofA Securities Buy
Jul-22-21 Initiated Citigroup Buy
Jun-15-21 Initiated JP Morgan Neutral
Jun-11-21 Initiated Morgan Stanley Equal-Weight
Jun-10-21 Initiated Evercore ISI Outperform
View All

Organon Co Stock (OGN) Latest News

pulisher
Oct 28, 2025

Why Organon (OGN) Stock Is Down Today - TradingView

Oct 28, 2025
pulisher
Oct 28, 2025

Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade

Oct 28, 2025
pulisher
Oct 28, 2025

Organon hit hard over ousted CEO scandal - The Pharma Letter

Oct 28, 2025
pulisher
Oct 28, 2025

The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha

Oct 28, 2025
pulisher
Oct 28, 2025

Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - FinancialContent

Oct 28, 2025
pulisher
Oct 28, 2025

Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire

Oct 28, 2025
pulisher
Oct 28, 2025

Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛

Oct 28, 2025
pulisher
Oct 28, 2025

Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize

Oct 28, 2025
pulisher
Oct 28, 2025

Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ

Oct 28, 2025
pulisher
Oct 27, 2025

Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Canada

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire

Oct 27, 2025
pulisher
Oct 27, 2025

Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma

Oct 27, 2025
pulisher
Oct 27, 2025

Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize

Oct 27, 2025
pulisher
Oct 27, 2025

This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - Barron's

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance

Oct 27, 2025
pulisher
Oct 27, 2025

Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC

Oct 27, 2025
pulisher
Oct 27, 2025

This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's

Oct 27, 2025
pulisher
Oct 27, 2025

Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Interim CEO and Board Chair; Reports Results of Audit Committee Investigation - New Jersey Business Magazine

Oct 27, 2025
pulisher
Oct 27, 2025

Organon cut to Underweight at Piper Sandler on internal control concerns - Seeking Alpha

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey as Interim CEO - citybiz

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co stock hits 52-week low at 7.26 USD By Investing.com - Investing.com South Africa

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Resigns After Probe Finds Improper Sales Practices - Bloomberg.com

Oct 27, 2025
pulisher
Oct 27, 2025

Organon appoints company executive Joseph Morrissey as interim CEO and board chair Carrie Cox as executive chair; announces results of audit committee investigation - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Kevin Ali to resign after probe into contraceptive sales - Reuters

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices - Stocktwits

Oct 27, 2025
pulisher
Oct 27, 2025

Organon & Co. Announces CEO Changes - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon stock tumbles after CEO resigns amid sales practice investigation By Investing.com - Investing.com UK

Oct 27, 2025
pulisher
Oct 27, 2025

Organon falls as CEO resigns after probe into contraceptive sales - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices - MarketScreener

Oct 27, 2025
pulisher
Oct 27, 2025

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation - Stock Titan

Oct 27, 2025
pulisher
Oct 27, 2025

Co. (7XP) stock considered safe havenMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Co. (7XP) stock in 20252025 Big Picture & Capital Efficiency Focused Ideas - newser.com

Oct 27, 2025
pulisher
Oct 26, 2025

Co. (7XP) stock survive global slowdown2025 Sector Review & Safe Entry Point Alerts - newser.com

Oct 26, 2025
pulisher
Oct 24, 2025

Assessing Organon Stock After a 39.5% Drop and Recent Portfolio Moves - Yahoo Finance

Oct 24, 2025
pulisher
Oct 23, 2025

Organon (OGN) Laps the Stock Market: Here's Why - sharewise.com

Oct 23, 2025
pulisher
Oct 23, 2025

Organon (OGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 23, 2025
pulisher
Oct 22, 2025

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com

Oct 22, 2025
pulisher
Oct 21, 2025

Organon & Co. (OGN) Stock Analysis: Exploring a 40.69% Potential Upside Amidst Healthcare Sector Challenges - DirectorsTalk Interviews

Oct 21, 2025
pulisher
Oct 19, 2025

Co. (7XP) stock good for long term investingJuly 2025 Recap & High Accuracy Buy Signal Tips - newser.com

Oct 19, 2025
pulisher
Oct 19, 2025

(OGN) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com

Oct 19, 2025
pulisher
Oct 18, 2025

Is Prolonged Revenue and EPS Decline Altering the Investment Case for Organon (OGN)? - Yahoo Finance

Oct 18, 2025
pulisher
Oct 18, 2025

Is Organon Co a good long term investmentPrice Momentum Alerts & Superior Capital Investment - earlytimes.in

Oct 18, 2025
pulisher
Oct 17, 2025

Organon (OGN) Stock Declines While Market Improves: Some Information for Investors - sharewise.com

Oct 17, 2025
pulisher
Oct 17, 2025

J.P. Morgan Keeps Their Sell Rating on Organon (OGN) - The Globe and Mail

Oct 17, 2025
pulisher
Oct 17, 2025

Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy - Seeking Alpha

Oct 17, 2025

Organon Co Stock (OGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general SNY
$51.41
price up icon 0.68%
drug_manufacturers_general PFE
$24.41
price down icon 0.33%
$117.65
price down icon 0.13%
$291.79
price down icon 0.11%
drug_manufacturers_general NVO
$52.41
price up icon 0.73%
drug_manufacturers_general MRK
$86.87
price down icon 0.15%
Cap:     |  Volume (24h):